NDA 050804 · Bausch and Lomb
Zylet
Loteprednol Etabonate, Tobramycin · Ophthalmic · Aminoglycoside Antibacterial
Last checked: Nov 19, 2026Latest source record: Oct 25, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 14, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
63
16 Phase 3, 0 recruiting
FAERS reports
400
116 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 20, 2026.
Loteprednol Etabonate and Tobramycin Ophthalmic Suspension 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Loteprednol...
Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 6, 2013 Supplement 18 · Efficacy Pediatric Written RequestPediatric Amendment 1Pediatric Medical Review
- Dec 14, 2004 Original approval · Type 4 - New Combination ReviewLetterLabel
1 products under this application
- ZYLET · LOTEPREDNOL ETABONATE 0.5%; TOBRAMYCIN 0.3% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseasePivotal-lookingCompleted
Kala Pharmaceuticals, Inc.Industry
NCT02813265 · 918 participants · Start Jun 2016 · Primary completion Oct 2017
Drug: KPI-121 0.25% Ophthalmic Suspension; Vehicle of KPI-121 0.25% Ophthalmic Suspension · For: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 60 sites in all
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye DiseasePivotal-lookingCompleted
Kala Pharmaceuticals, Inc.Industry
NCT02819284 · 909 participants · Start Jun 2016 · Primary completion Sep 2017
Drug: KPI-121 0.25% Ophthalmic Suspension; Vehicle of KPI-121 0.25% Ophthalmic Suspension · For: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Sites: Birmingham, Alabama; Chandler, Arizona; Jonesboro, Arkansas · 62 sites in all
- LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT02786901 · 600 participants · Start Jun 2016 · Primary completion Jun 13, 2017
Drug: Loteprednol Etabonate Ophthalmic Gel dosed TID; Loteprednol Etabonate Ophthalmic Gel dosed BID and 1 more · For: Cataract; Pain; Ocular Inflammation
Sites: Phoenix, Arizona; Oceanside, California; Miami, Florida · 6 sites in all
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and PainPivotal-lookingCompleted
Kala Pharmaceuticals, Inc.Industry
NCT02793817 · 520 participants · Start Jun 2016 · Primary completion Mar 2017
Drug: KPI-121 1% Ophthalmic Suspension dosed BID; Vehicle of KPI-121 Ophthalmic Suspension dosed BID · For: Post Surgical Ocular Inflammation and Pain
Sites: Chandler, Arizona; Phoenix, Arizona; Artesia, California · 35 sites in all
- Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01996839 · 514 participants · Start Dec 2013 · Primary completion May 2014
Drug: Loteprednol Etabonate Gel (BID); Loteprednol Etabonate Gel (TID) and 2 more · For: Inflammation; Pain; Cataract
Sites: Bridgewater, New Jersey
- Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01060072 · 407 participants · Start Feb 2010 · Primary completion Sep 2010
Drug: Loteprednol etabonate; Vehicle of Loteprednol Etabonate · For: Inflammation; Pain
Sites: Rochester, New York
- Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT01010633 · 406 participants · Start Nov 2009 · Primary completion Jun 2010
Drug: Vehicle of Loteprednol Etabonate; Loteprednol Etabonate · For: Inflammation; Pain
Sites: Rochester, New York
- Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract SurgeryPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00645671 · 400 participants · Start Mar 2008 · Primary completion Mar 2009
Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment; Vehicle of Loteprednol Etabonate Ophthalmic Ointment · For: Ocular Inflammation
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye pain49
- ocular hyperaemia48
- eye irritation47
- drug ineffective41
- vision blurred31
- headache30
- lacrimation increased28
- eye pruritus21
- chronic kidney disease20
- eye swelling19
- condition aggravated18
- drug hypersensitivity18
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 24 |
| 2008 | 18 |
| 2009 | 4 |
| 2010 | 26 |
| 2011 | 24 |
| 2012 | 20 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 20 |
| 2016 | 24 |
| 2017 | 32 |
| 2018 | 39 |
| 2019 | 56 |
| 2020 | 22 |
| 2021 | 22 |
| 2022 | 26 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 10 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zylet (Tobramycin/Lotepred Etab)
2024 spending
$3.1M
Beneficiaries
5,598
8,050 claims
Per beneficiary
$557
$63.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,398,226 |
| 2021 | $3,490,438 |
| 2022 | $3,812,357 |
| 2023 | $3,777,050 |
| 2024 | $3,120,370 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis.
Wu LQ, Chen X, Lou H, et al. · Curr Med Res Opin 2015 · Meta-Analysis
- Topical corticosteroids for dry eye.
Liu SH, Saldanha IJ, Abraham AG, et al. · Cochrane Database Syst Rev 2022 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparison of 2 regimens of loteprednol etabonate and bromfenac for cataract surgery.
Al-Awadi A, Tokko HA, Chan CC, et al. · Can J Ophthalmol 2019 · Randomized Controlled Trial, Equivalence Trial
- Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis.
Comstock TL, DeCory HH · Ocul Immunol Inflamm 2017 · Comparative Study, Multicenter Study
- Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children.
Hardas A, Singh N, Mohanty A, et al. · Eye (Lond) 2022 · Randomized Controlled Trial
- Efficacy and safety of loteprednol etabonate versus fluorometholone in the treatment of patients after corneal refractive surgery: a meta-analysis.
Zhang X, Shen Z, Sun H, et al. · Int Ophthalmol 2023 · Meta-Analysis
Sponsor: Bausch and Lomb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.